Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Want to cut your energy bills? Here’s how five experts are doing it 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
JERSEY, Channel Islands, May 31, 2017 -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2017 Global Healthcare Conference on Wednesday, June 7, 2017 at 3:00 p.m. Eastern Time at the Grand Hyatt New York.
A webcast of the presentation will be available online from the investor relations page of the Company's corporate website at www.quotientbd.com. A webcast replay will be archived on the website for approximately 90 days.
About Quotient Limited
Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.
The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.
CONTACT: Chris Lindop, Chief Financial Officer — [email protected]; +41 (0)799 61 69 38
